PolyPid to Participate in The Citizens Life Sciences Conference

PolyPid (Nasdaq: PYPD), a late-stage biopharma company focused on improving surgical outcomes, has announced its participation in The Citizens Life Sciences Conference in New York.

Rhea-AI Summary

PolyPid (Nasdaq: PYPD), a late-stage biopharma company focused on improving surgical outcomes, has announced its participation in The Citizens Life Sciences Conference in New York. The company's management will engage in a fireside chat on Wednesday, May 7, 2025, at 10:30 AM ET.

During the two-day conference, scheduled for May 7-8, 2025, the PolyPid management team will also be available for one-on-one investor meetings. Interested investors can arrange meetings through their Citizens JMP representatives.

Argus Session date unavailable

-1.45% session move Open Argus

Details

News Market Reaction – PYPD

The recorded move for PYPD in the trading session of this news was -1.45%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PETACH TIKVA, Israel, April 22, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the Company’s management will participate in a fireside chat at The Citizens Life Sciences Conference taking place in New York, NY, from May 7-8, 2025.

Citizens Life Sciences Conference Fireside Chat
Date:	Wednesday, May 7, 2025
Time:	10:30 AM ET

The PolyPid management team will participate in one-on-one investor meetings during this event. Investors interested in meeting with PolyPid around the conference should contact their Citizens JMP representative.

About PolyPid

PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX₁₀₀ is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma.

For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.

Contacts:
PolyPid Ltd. 
Ori Warshavsky
COO – US
908-858-5995
IR@Polypid.com

Investors:
Brian Ritchie
LifeSci Advisors
212-915-2578
britchie@lifesciadvisors.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is PolyPid's fireside chat at the Citizens Life Sciences Conference 2025?

PolyPid's fireside chat is scheduled for Wednesday, May 7, 2025, at 10:30 AM ET in New York.

How can investors schedule meetings with PYPD management at the Citizens Conference?

Investors interested in meeting with PolyPid should contact their Citizens JMP representative to arrange one-on-one meetings.

What is the duration of the Citizens Life Sciences Conference where PYPD is presenting?

The Citizens Life Sciences Conference is a two-day event taking place from May 7-8, 2025.

What type of company is PYPD and what is their focus?

PYPD (PolyPid) is a late-stage biopharma company focused on improving surgical outcomes.